Xeris Pharmaceuticals Stock Filter Stocks by Fundamentals
| XERS Stock | USD 3.20 0.02 0.62% |
Xeris Pharmaceuticals fundamentals help investors to digest information that contributes to Xeris Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Xeris Stock. The fundamental analysis module provides a way to measure Xeris Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xeris Pharmaceuticals stock.
Xeris | Shares Owned by Institutions |
Xeris Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xeris Pharmaceuticals from analyzing Xeris Pharmaceuticals' financial statements. These drivers represent accounts that assess Xeris Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xeris Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 209.8M | 231.5M | 180.4M | 323.5M | 291.2M | 305.7M | |
| Enterprise Value | 230.6M | 307.6M | 256.5M | 485.3M | 436.8M | 458.6M |
Xeris Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xeris Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xeris Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xeris Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Xeris Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Xeris Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Xeris Pharmaceuticals' value.| Shares | Millennium Management Llc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Walleye Trading Advisors, Llc | 2024-09-30 | 1.1 M | Aqr Capital Management Llc | 2024-09-30 | 1.1 M | Redmile Group, Llc | 2024-09-30 | 1 M | Bank Of America Corp | 2024-09-30 | 1 M | D. E. Shaw & Co Lp | 2024-09-30 | 985 K | Goldman Sachs Group Inc | 2024-09-30 | 836.4 K | Kennedy Capital Management Inc | 2024-09-30 | 604.9 K | Blackrock Inc | 2024-09-30 | 10.7 M | Vanguard Group Inc | 2024-09-30 | 7.8 M |
Xeris Fundamentals
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 678.62 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.99 % | ||||
| Number Of Shares Shorted | 10.19 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 2.66 X | ||||
| Revenue | 163.91 M | ||||
| Gross Profit | 152.44 M | ||||
| EBITDA | (23.73 M) | ||||
| Net Income | (62.26 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 229.19 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (47.02 M) | ||||
| Short Ratio | 6.21 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 4.77 | ||||
| Number Of Employees | 377 | ||||
| Beta | 1.29 | ||||
| Market Capitalization | 497.93 M | ||||
| Total Asset | 322.6 M | ||||
| Retained Earnings | (617.02 M) | ||||
| Working Capital | 61.07 M | ||||
| Net Asset | 322.6 M |
About Xeris Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.